Interleukin-2 and dendritic cells as adjuvants for surgical therapy of tumours associated with human papillomavirus type 16

0191584 - UMG-J 20033052 RIV NL eng J - Journal Article
Bubeník, Jan - Mikyšková, Romana - Vonka, V. - Mendoza, Luis - Šímová, Jana - Šmahel, M. - Indrová, Marie
Interleukin-2 and dendritic cells as adjuvants for surgical therapy of tumours associated with human papillomavirus type 16.
Vaccine. Roč. 21, 9-10 (2003), s. 891-896. ISSN 0264-410X. E-ISSN 1873-2518
R&D Projects: GA MZd NC7148; GA ČR GA301/00/0114; GA ČR GA301/01/0985; GA AV ČR IAA7052002; GA AV ČR IAA5052203
Grant - others:Liga proti rakovině(CZ) -
Institutional research plan: CEZ:AV0Z5052915
Keywords : interleukin-2 * HPV 16 * dendritic cells
Subject RIV: FD - Oncology ; Hematology
Impact factor: 3.007, year: 2003

Moderately immunogenic HPV16-associated tumours, MHC class I+ and class I-, were used to examine the adjuvant effects of IL-2 and dendritic cells for surgical therapy. It has been found that in both types of tumours recombinant IL-2 and IL-2 gene-modified vaccines substantially reduced the tumour recurrence rate and inhibited tumour growth. The dendritic cells were effective only in surgical therapy of MHC class I+ tumours.
Permanent Link: http://hdl.handle.net/11104/0087326